Pharma & Healthcare
Global HIV Prevention Drug Market Outlook, In‑Depth Analysis & Forecast to 2031
- Nov 04, 25
- ID: 570852
- Pages: 119
- Figures: 122
- Views: 25
Report Includes:
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global HIV Prevention Drug market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Gilead Sciences
ViiV Healthcare
Segment by Type
Lenacapavir
Cabotegravir
Segment by Application
Hospital
Clinic
Others
Sales by Region
North America
U.S.
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia (Indonesia, Vietnam, Thailand)
India
Europe
Germany
France
U.K.
Italy
Russia
Central South America
Brazil
Argentina
Middle East, Africa
Turkey
Egypt
GCC Countries
South Africa
Chapter Outline
Chapter 1: Defines the HIV Prevention Drug study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global HIV Prevention Drug market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Gilead Sciences
ViiV Healthcare
Segment by Type
Lenacapavir
Cabotegravir
Segment by Application
Hospital
Clinic
Others
Sales by Region
North America
U.S.
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia (Indonesia, Vietnam, Thailand)
India
Europe
Germany
France
U.K.
Italy
Russia
Central South America
Brazil
Argentina
Middle East, Africa
Turkey
Egypt
GCC Countries
South Africa
Chapter Outline
Chapter 1: Defines the HIV Prevention Drug study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
1 Study Coverage
1.1 Introduction to HIV Prevention Drug: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global HIV Prevention Drug Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Lenacapavir
1.2.3 Cabotegravir
1.3 Market Segmentation by Application
1.3.1 Global HIV Prevention Drug Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global HIV Prevention Drug Revenue Estimates and Forecasts 2020-2031
2.2 Global HIV Prevention Drug Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global HIV Prevention Drug Sales Estimates and Forecasts 2020-2031
2.4 Global HIV Prevention Drug Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global HIV Prevention Drug Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global HIV Prevention Drug Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 Lenacapavir Market Size by Manufacturers
3.6 Global HIV Prevention Drug Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global HIV Prevention Drug Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global HIV Prevention Drug Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global HIV Prevention Drug Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global HIV Prevention Drug Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America HIV Prevention Drug Sales and Revenue by Type (2020-2031)
6.4 North America HIV Prevention Drug Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America HIV Prevention Drug Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe HIV Prevention Drug Sales and Revenue by Type (2020-2031)
7.4 Europe HIV Prevention Drug Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe HIV Prevention Drug Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific HIV Prevention Drug Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific HIV Prevention Drug Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific HIV Prevention Drug Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America HIV Prevention Drug Sales and Revenue by Type (2020-2031)
9.4 Central and South America HIV Prevention Drug Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America HIV Prevention Drug Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa HIV Prevention Drug Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa HIV Prevention Drug Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa HIV Prevention Drug Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Gilead Sciences
11.1.1 Gilead Sciences Corporation Information
11.1.2 Gilead Sciences Business Overview
11.1.3 Gilead Sciences HIV Prevention Drug Product Models, Descriptions and Specifications
11.1.4 Gilead Sciences HIV Prevention Drug Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 Gilead Sciences HIV Prevention Drug Sales by Product in 2024
11.1.6 Gilead Sciences HIV Prevention Drug Sales by Application in 2024
11.1.7 Gilead Sciences HIV Prevention Drug Sales by Geographic Area in 2024
11.1.8 Gilead Sciences HIV Prevention Drug SWOT Analysis
11.1.9 Gilead Sciences Recent Developments
11.2 ViiV Healthcare
11.2.1 ViiV Healthcare Corporation Information
11.2.2 ViiV Healthcare Business Overview
11.2.3 ViiV Healthcare HIV Prevention Drug Product Models, Descriptions and Specifications
11.2.4 ViiV Healthcare HIV Prevention Drug Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 ViiV Healthcare HIV Prevention Drug Sales by Product in 2024
11.2.6 ViiV Healthcare HIV Prevention Drug Sales by Application in 2024
11.2.7 ViiV Healthcare HIV Prevention Drug Sales by Geographic Area in 2024
11.2.8 ViiV Healthcare HIV Prevention Drug SWOT Analysis
11.2.9 ViiV Healthcare Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 HIV Prevention Drug Industry Chain
12.2 HIV Prevention Drug Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 HIV Prevention Drug Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 HIV Prevention Drug Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 HIV Prevention Drug Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global HIV Prevention Drug Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
1.1 Introduction to HIV Prevention Drug: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global HIV Prevention Drug Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Lenacapavir
1.2.3 Cabotegravir
1.3 Market Segmentation by Application
1.3.1 Global HIV Prevention Drug Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global HIV Prevention Drug Revenue Estimates and Forecasts 2020-2031
2.2 Global HIV Prevention Drug Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global HIV Prevention Drug Sales Estimates and Forecasts 2020-2031
2.4 Global HIV Prevention Drug Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global HIV Prevention Drug Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global HIV Prevention Drug Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 Lenacapavir Market Size by Manufacturers
3.6 Global HIV Prevention Drug Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global HIV Prevention Drug Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global HIV Prevention Drug Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global HIV Prevention Drug Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global HIV Prevention Drug Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America HIV Prevention Drug Sales and Revenue by Type (2020-2031)
6.4 North America HIV Prevention Drug Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America HIV Prevention Drug Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe HIV Prevention Drug Sales and Revenue by Type (2020-2031)
7.4 Europe HIV Prevention Drug Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe HIV Prevention Drug Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific HIV Prevention Drug Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific HIV Prevention Drug Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific HIV Prevention Drug Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America HIV Prevention Drug Sales and Revenue by Type (2020-2031)
9.4 Central and South America HIV Prevention Drug Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America HIV Prevention Drug Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa HIV Prevention Drug Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa HIV Prevention Drug Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa HIV Prevention Drug Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Gilead Sciences
11.1.1 Gilead Sciences Corporation Information
11.1.2 Gilead Sciences Business Overview
11.1.3 Gilead Sciences HIV Prevention Drug Product Models, Descriptions and Specifications
11.1.4 Gilead Sciences HIV Prevention Drug Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 Gilead Sciences HIV Prevention Drug Sales by Product in 2024
11.1.6 Gilead Sciences HIV Prevention Drug Sales by Application in 2024
11.1.7 Gilead Sciences HIV Prevention Drug Sales by Geographic Area in 2024
11.1.8 Gilead Sciences HIV Prevention Drug SWOT Analysis
11.1.9 Gilead Sciences Recent Developments
11.2 ViiV Healthcare
11.2.1 ViiV Healthcare Corporation Information
11.2.2 ViiV Healthcare Business Overview
11.2.3 ViiV Healthcare HIV Prevention Drug Product Models, Descriptions and Specifications
11.2.4 ViiV Healthcare HIV Prevention Drug Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 ViiV Healthcare HIV Prevention Drug Sales by Product in 2024
11.2.6 ViiV Healthcare HIV Prevention Drug Sales by Application in 2024
11.2.7 ViiV Healthcare HIV Prevention Drug Sales by Geographic Area in 2024
11.2.8 ViiV Healthcare HIV Prevention Drug SWOT Analysis
11.2.9 ViiV Healthcare Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 HIV Prevention Drug Industry Chain
12.2 HIV Prevention Drug Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 HIV Prevention Drug Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 HIV Prevention Drug Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 HIV Prevention Drug Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global HIV Prevention Drug Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
Table 1. Global HIV Prevention Drug Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global HIV Prevention Drug Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global HIV Prevention Drug Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global HIV Prevention Drug Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global HIV Prevention Drug Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global HIV Prevention Drug Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
Table 7. Global HIV Prevention Drug Sales by Region (2020-2025) & (K Units)
Table 8. Global HIV Prevention Drug Sales by Region (2026-2031) & (K Units)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global HIV Prevention Drug Sales by Manufacturers (2020-2025) & (K Units)
Table 11. Global HIV Prevention Drug Sales Share by Manufacturers (2020-2025)
Table 12. Global HIV Prevention Drug Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global HIV Prevention Drug Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global HIV Prevention Drug by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in HIV Prevention Drug as of 2024)
Table 16. Global HIV Prevention Drug Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global HIV Prevention Drug Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
Table 18. Key Manufacturers HIV Prevention Drug Manufacturing Base and Headquarters
Table 19. Global HIV Prevention Drug Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global HIV Prevention Drug Sales by Type (2020-2025) & (K Units)
Table 23. Global HIV Prevention Drug Sales by Type (2026-2031) & (K Units)
Table 24. Global HIV Prevention Drug Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global HIV Prevention Drug Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global HIV Prevention Drug ASP by Type (2020-2031) & (US$/Unit)
Table 27. Technical Specifications by Key Product Type
Table 28. Global HIV Prevention Drug Sales by Application (2020-2025) & (K Units)
Table 29. Global HIV Prevention Drug Sales by Application (2026-2031) & (K Units)
Table 30. HIV Prevention Drug High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global HIV Prevention Drug Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global HIV Prevention Drug Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global HIV Prevention Drug ASP by Application (2020-2031) & (US$/Unit)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America HIV Prevention Drug Growth Accelerators and Market Barriers
Table 37. North America HIV Prevention Drug Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America HIV Prevention Drug Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 39. Europe HIV Prevention Drug Growth Accelerators and Market Barriers
Table 40. Europe HIV Prevention Drug Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe HIV Prevention Drug Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific HIV Prevention Drug Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific HIV Prevention Drug Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific HIV Prevention Drug Growth Accelerators and Market Barriers
Table 45. Southeast Asia HIV Prevention Drug Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America HIV Prevention Drug Investment Opportunities and Key Challenges
Table 47. Central and South America HIV Prevention Drug Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa HIV Prevention Drug Investment Opportunities and Key Challenges
Table 49. Middle East and Africa HIV Prevention Drug Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. Gilead Sciences Corporation Information
Table 51. Gilead Sciences Description and Major Businesses
Table 52. Gilead Sciences Product Models, Descriptions and Specifications
Table 53. Gilead Sciences Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 54. Gilead Sciences Sales Value Proportion by Product in 2024
Table 55. Gilead Sciences Sales Value Proportion by Application in 2024
Table 56. Gilead Sciences Sales Value Proportion by Geographic Area in 2024
Table 57. Gilead Sciences HIV Prevention Drug SWOT Analysis
Table 58. Gilead Sciences Recent Developments
Table 59. ViiV Healthcare Corporation Information
Table 60. ViiV Healthcare Description and Major Businesses
Table 61. ViiV Healthcare Product Models, Descriptions and Specifications
Table 62. ViiV Healthcare Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 63. ViiV Healthcare Sales Value Proportion by Product in 2024
Table 64. ViiV Healthcare Sales Value Proportion by Application in 2024
Table 65. ViiV Healthcare Sales Value Proportion by Geographic Area in 2024
Table 66. ViiV Healthcare HIV Prevention Drug SWOT Analysis
Table 67. ViiV Healthcare Recent Developments
Table 68. Key Raw Materials Distribution
Table 69. Raw Materials Key Suppliers
Table 70. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 71. Milestones in Production Technology Evolution
Table 72. Distributors List
Table 73. Market Trends and Market Evolution
Table 74. Market Drivers and Opportunities
Table 75. Market Challenges, Risks, and Restraints
Table 76. Research Programs/Design for This Report
Table 77. Key Data Information from Secondary Sources
Table 78. Key Data Information from Primary Sources
List of Figures
Figure 1. HIV Prevention Drug Product Picture
Figure 2. Global HIV Prevention Drug Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Lenacapavir Product Picture
Figure 4. Cabotegravir Product Picture
Figure 5. Global HIV Prevention Drug Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 6. Hospital
Figure 7. Clinic
Figure 8. Others
Figure 9. HIV Prevention Drug Report Years Considered
Figure 10. Global HIV Prevention Drug Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 11. Global HIV Prevention Drug Revenue (2020-2031) & (US$ Million)
Figure 12. Global HIV Prevention Drug Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 13. Global HIV Prevention Drug Revenue Market Share by Region (2020-2031)
Figure 14. Global HIV Prevention Drug Sales (2020-2031) & (K Units)
Figure 15. Global HIV Prevention Drug Sales (CAGR) by Region (2020-2031) (K Units)
Figure 16. Global HIV Prevention Drug Sales Market Share by Region (2020-2031)
Figure 17. Top 5 and Top 10 Manufacturers HIV Prevention Drug Sales Volume Market Share in 2024
Figure 18. Global HIV Prevention Drug Revenue Market Share Ranking (2024)
Figure 19. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 20. Lenacapavir Revenue Market Share by Manufacturer in 2024
Figure 21. Cabotegravir Revenue Market Share by Manufacturer in 2024
Figure 22. Global HIV Prevention Drug Sales Market Share by Type (2020-2031)
Figure 23. Global HIV Prevention Drug Revenue Market Share by Type (2020-2031)
Figure 24. Global HIV Prevention Drug Sales Market Share by Application (2020-2031)
Figure 25. Global HIV Prevention Drug Revenue Market Share by Application (2020-2031)
Figure 26. North America HIV Prevention Drug Sales YoY (2020-2031) & (K Units)
Figure 27. North America HIV Prevention Drug Revenue YoY (2020-2031) & (US$ Million)
Figure 28. North America Top 5 Manufacturers HIV Prevention Drug Sales Revenue (US$ Million) in 2024
Figure 29. North America HIV Prevention Drug Sales Volume (K Units) by Type (2020- 2031)
Figure 30. North America HIV Prevention Drug Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 31. North America HIV Prevention Drug Sales Volume (K Units) by Application (2020-2031)
Figure 32. North America HIV Prevention Drug Sales Revenue (US$ Million) by Application (2020-2031)
Figure 33. US HIV Prevention Drug Revenue (2020-2031) & (US$ Million)
Figure 34. Canada HIV Prevention Drug Revenue (2020-2031) & (US$ Million)
Figure 35. Mexico HIV Prevention Drug Revenue (2020-2031) & (US$ Million)
Figure 36. Europe HIV Prevention Drug Sales YoY (2020-2031) & (K Units)
Figure 37. Europe HIV Prevention Drug Revenue YoY (2020-2031) & (US$ Million)
Figure 38. Europe Top 5 Manufacturers HIV Prevention Drug Sales Revenue (US$ Million) in 2024
Figure 39. Europe HIV Prevention Drug Sales Volume (K Units) by Type (2020-2031)
Figure 40. Europe HIV Prevention Drug Sales Revenue (US$ Million) by Type (2020-2031)
Figure 41. Europe HIV Prevention Drug Sales Volume (K Units) by Application (2020-2031)
Figure 42. Europe HIV Prevention Drug Sales Revenue (US$ Million) by Application (2020-2031)
Figure 43. Germany HIV Prevention Drug Revenue (2020-2031) & (US$ Million)
Figure 44. France HIV Prevention Drug Revenue (2020-2031) & (US$ Million)
Figure 45. U.K. HIV Prevention Drug Revenue (2020-2031) & (US$ Million)
Figure 46. Italy HIV Prevention Drug Revenue (2020-2031) & (US$ Million)
Figure 47. Russia HIV Prevention Drug Revenue (2020-2031) & (US$ Million)
Figure 48. Asia-Pacific HIV Prevention Drug Sales YoY (2020-2031) & (K Units)
Figure 49. Asia-Pacific HIV Prevention Drug Revenue YoY (2020-2031) & (US$ Million)
Figure 50. Asia-Pacific Top 8 Manufacturers HIV Prevention Drug Sales Revenue (US$ Million) in 2024
Figure 51. Asia-Pacific HIV Prevention Drug Sales Volume (K Units) by Type (2020- 2031)
Figure 52. Asia-Pacific HIV Prevention Drug Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 53. Asia-Pacific HIV Prevention Drug Sales Volume (K Units) by Application (2020-2031)
Figure 54. Asia-Pacific HIV Prevention Drug Sales Revenue (US$ Million) by Application (2020-2031)
Figure 55. Indonesia HIV Prevention Drug Revenue (2020-2031) & (US$ Million)
Figure 56. Japan HIV Prevention Drug Revenue (2020-2031) & (US$ Million)
Figure 57. South Korea HIV Prevention Drug Revenue (2020-2031) & (US$ Million)
Figure 58. China Taiwan HIV Prevention Drug Revenue (2020-2031) & (US$ Million)
Figure 59. India HIV Prevention Drug Revenue (2020-2031) & (US$ Million)
Figure 60. Central and South America HIV Prevention Drug Sales YoY (2020-2031) & (K Units)
Figure 61. Central and South America HIV Prevention Drug Revenue YoY (2020-2031) & (US$ Million)
Figure 62. Central and South America Top 5 Manufacturers HIV Prevention Drug Sales Revenue (US$ Million) in 2024
Figure 63. Central and South America HIV Prevention Drug Sales Volume (K Units) by Type (2021-2031)
Figure 64. Central and South America HIV Prevention Drug Sales Revenue (US$ Million) by Type (2020-2031)
Figure 65. Central and South America HIV Prevention Drug Sales Volume (K Units) by Application (2020-2031)
Figure 66. Central and South America HIV Prevention Drug Sales Revenue (US$ Million) by Application (2020-2031)
Figure 67. Brazil HIV Prevention Drug Revenue (2020-2025) & (US$ Million)
Figure 68. Argentina HIV Prevention Drug Revenue (2020-2025) & (US$ Million)
Figure 69. Middle East, and Africa HIV Prevention Drug Sales YoY (2020-2031) & (K Units)
Figure 70. Middle East and Africa HIV Prevention Drug Revenue YoY (2020-2031) & (US$ Million)
Figure 71. Middle East and Africa Top 5 Manufacturers HIV Prevention Drug Sales Revenue (US$ Million) in 2024
Figure 72. Middle East and Africa HIV Prevention Drug Sales Volume (K Units) by Type (2021-2031)
Figure 73. South America HIV Prevention Drug Sales Revenue (US$ Million) by Type (2020-2031)
Figure 74. Middle East and Africa HIV Prevention Drug Sales Volume (K Units) by Application (2020-2031)
Figure 75. Middle East and Africa HIV Prevention Drug Sales Revenue (US$ Million) by Application (2020-2031)
Figure 76. GCC Countries HIV Prevention Drug Revenue (2020-2025) & (US$ Million)
Figure 77. Turkey HIV Prevention Drug Revenue (2020-2025) & (US$ Million)
Figure 78. Egypt HIV Prevention Drug Revenue (2020-2025) & (US$ Million)
Figure 79. South Africa HIV Prevention Drug Revenue (2020-2025) & (US$ Million)
Figure 80. HIV Prevention Drug Industry Chain Mapping
Figure 81. Regional HIV Prevention Drug Manufacturing Base Distribution (%)
Figure 82. Global HIV Prevention Drug Production Market Share by Region (2020-2031)
Figure 83. HIV Prevention Drug Production Process
Figure 84. Regional HIV Prevention Drug Production Cost Structure
Figure 85. Channels of Distribution (Direct Vs Distribution)
Figure 86. Bottom-up and Top-down Approaches for This Report
Figure 87. Data Triangulation
Figure 88. Key Executives Interviewed
Table 1. Global HIV Prevention Drug Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global HIV Prevention Drug Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global HIV Prevention Drug Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global HIV Prevention Drug Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global HIV Prevention Drug Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global HIV Prevention Drug Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
Table 7. Global HIV Prevention Drug Sales by Region (2020-2025) & (K Units)
Table 8. Global HIV Prevention Drug Sales by Region (2026-2031) & (K Units)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global HIV Prevention Drug Sales by Manufacturers (2020-2025) & (K Units)
Table 11. Global HIV Prevention Drug Sales Share by Manufacturers (2020-2025)
Table 12. Global HIV Prevention Drug Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global HIV Prevention Drug Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global HIV Prevention Drug by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in HIV Prevention Drug as of 2024)
Table 16. Global HIV Prevention Drug Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global HIV Prevention Drug Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
Table 18. Key Manufacturers HIV Prevention Drug Manufacturing Base and Headquarters
Table 19. Global HIV Prevention Drug Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global HIV Prevention Drug Sales by Type (2020-2025) & (K Units)
Table 23. Global HIV Prevention Drug Sales by Type (2026-2031) & (K Units)
Table 24. Global HIV Prevention Drug Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global HIV Prevention Drug Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global HIV Prevention Drug ASP by Type (2020-2031) & (US$/Unit)
Table 27. Technical Specifications by Key Product Type
Table 28. Global HIV Prevention Drug Sales by Application (2020-2025) & (K Units)
Table 29. Global HIV Prevention Drug Sales by Application (2026-2031) & (K Units)
Table 30. HIV Prevention Drug High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global HIV Prevention Drug Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global HIV Prevention Drug Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global HIV Prevention Drug ASP by Application (2020-2031) & (US$/Unit)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America HIV Prevention Drug Growth Accelerators and Market Barriers
Table 37. North America HIV Prevention Drug Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America HIV Prevention Drug Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 39. Europe HIV Prevention Drug Growth Accelerators and Market Barriers
Table 40. Europe HIV Prevention Drug Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe HIV Prevention Drug Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific HIV Prevention Drug Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific HIV Prevention Drug Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific HIV Prevention Drug Growth Accelerators and Market Barriers
Table 45. Southeast Asia HIV Prevention Drug Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America HIV Prevention Drug Investment Opportunities and Key Challenges
Table 47. Central and South America HIV Prevention Drug Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa HIV Prevention Drug Investment Opportunities and Key Challenges
Table 49. Middle East and Africa HIV Prevention Drug Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. Gilead Sciences Corporation Information
Table 51. Gilead Sciences Description and Major Businesses
Table 52. Gilead Sciences Product Models, Descriptions and Specifications
Table 53. Gilead Sciences Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 54. Gilead Sciences Sales Value Proportion by Product in 2024
Table 55. Gilead Sciences Sales Value Proportion by Application in 2024
Table 56. Gilead Sciences Sales Value Proportion by Geographic Area in 2024
Table 57. Gilead Sciences HIV Prevention Drug SWOT Analysis
Table 58. Gilead Sciences Recent Developments
Table 59. ViiV Healthcare Corporation Information
Table 60. ViiV Healthcare Description and Major Businesses
Table 61. ViiV Healthcare Product Models, Descriptions and Specifications
Table 62. ViiV Healthcare Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 63. ViiV Healthcare Sales Value Proportion by Product in 2024
Table 64. ViiV Healthcare Sales Value Proportion by Application in 2024
Table 65. ViiV Healthcare Sales Value Proportion by Geographic Area in 2024
Table 66. ViiV Healthcare HIV Prevention Drug SWOT Analysis
Table 67. ViiV Healthcare Recent Developments
Table 68. Key Raw Materials Distribution
Table 69. Raw Materials Key Suppliers
Table 70. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 71. Milestones in Production Technology Evolution
Table 72. Distributors List
Table 73. Market Trends and Market Evolution
Table 74. Market Drivers and Opportunities
Table 75. Market Challenges, Risks, and Restraints
Table 76. Research Programs/Design for This Report
Table 77. Key Data Information from Secondary Sources
Table 78. Key Data Information from Primary Sources
List of Figures
Figure 1. HIV Prevention Drug Product Picture
Figure 2. Global HIV Prevention Drug Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Lenacapavir Product Picture
Figure 4. Cabotegravir Product Picture
Figure 5. Global HIV Prevention Drug Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 6. Hospital
Figure 7. Clinic
Figure 8. Others
Figure 9. HIV Prevention Drug Report Years Considered
Figure 10. Global HIV Prevention Drug Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 11. Global HIV Prevention Drug Revenue (2020-2031) & (US$ Million)
Figure 12. Global HIV Prevention Drug Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 13. Global HIV Prevention Drug Revenue Market Share by Region (2020-2031)
Figure 14. Global HIV Prevention Drug Sales (2020-2031) & (K Units)
Figure 15. Global HIV Prevention Drug Sales (CAGR) by Region (2020-2031) (K Units)
Figure 16. Global HIV Prevention Drug Sales Market Share by Region (2020-2031)
Figure 17. Top 5 and Top 10 Manufacturers HIV Prevention Drug Sales Volume Market Share in 2024
Figure 18. Global HIV Prevention Drug Revenue Market Share Ranking (2024)
Figure 19. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 20. Lenacapavir Revenue Market Share by Manufacturer in 2024
Figure 21. Cabotegravir Revenue Market Share by Manufacturer in 2024
Figure 22. Global HIV Prevention Drug Sales Market Share by Type (2020-2031)
Figure 23. Global HIV Prevention Drug Revenue Market Share by Type (2020-2031)
Figure 24. Global HIV Prevention Drug Sales Market Share by Application (2020-2031)
Figure 25. Global HIV Prevention Drug Revenue Market Share by Application (2020-2031)
Figure 26. North America HIV Prevention Drug Sales YoY (2020-2031) & (K Units)
Figure 27. North America HIV Prevention Drug Revenue YoY (2020-2031) & (US$ Million)
Figure 28. North America Top 5 Manufacturers HIV Prevention Drug Sales Revenue (US$ Million) in 2024
Figure 29. North America HIV Prevention Drug Sales Volume (K Units) by Type (2020- 2031)
Figure 30. North America HIV Prevention Drug Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 31. North America HIV Prevention Drug Sales Volume (K Units) by Application (2020-2031)
Figure 32. North America HIV Prevention Drug Sales Revenue (US$ Million) by Application (2020-2031)
Figure 33. US HIV Prevention Drug Revenue (2020-2031) & (US$ Million)
Figure 34. Canada HIV Prevention Drug Revenue (2020-2031) & (US$ Million)
Figure 35. Mexico HIV Prevention Drug Revenue (2020-2031) & (US$ Million)
Figure 36. Europe HIV Prevention Drug Sales YoY (2020-2031) & (K Units)
Figure 37. Europe HIV Prevention Drug Revenue YoY (2020-2031) & (US$ Million)
Figure 38. Europe Top 5 Manufacturers HIV Prevention Drug Sales Revenue (US$ Million) in 2024
Figure 39. Europe HIV Prevention Drug Sales Volume (K Units) by Type (2020-2031)
Figure 40. Europe HIV Prevention Drug Sales Revenue (US$ Million) by Type (2020-2031)
Figure 41. Europe HIV Prevention Drug Sales Volume (K Units) by Application (2020-2031)
Figure 42. Europe HIV Prevention Drug Sales Revenue (US$ Million) by Application (2020-2031)
Figure 43. Germany HIV Prevention Drug Revenue (2020-2031) & (US$ Million)
Figure 44. France HIV Prevention Drug Revenue (2020-2031) & (US$ Million)
Figure 45. U.K. HIV Prevention Drug Revenue (2020-2031) & (US$ Million)
Figure 46. Italy HIV Prevention Drug Revenue (2020-2031) & (US$ Million)
Figure 47. Russia HIV Prevention Drug Revenue (2020-2031) & (US$ Million)
Figure 48. Asia-Pacific HIV Prevention Drug Sales YoY (2020-2031) & (K Units)
Figure 49. Asia-Pacific HIV Prevention Drug Revenue YoY (2020-2031) & (US$ Million)
Figure 50. Asia-Pacific Top 8 Manufacturers HIV Prevention Drug Sales Revenue (US$ Million) in 2024
Figure 51. Asia-Pacific HIV Prevention Drug Sales Volume (K Units) by Type (2020- 2031)
Figure 52. Asia-Pacific HIV Prevention Drug Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 53. Asia-Pacific HIV Prevention Drug Sales Volume (K Units) by Application (2020-2031)
Figure 54. Asia-Pacific HIV Prevention Drug Sales Revenue (US$ Million) by Application (2020-2031)
Figure 55. Indonesia HIV Prevention Drug Revenue (2020-2031) & (US$ Million)
Figure 56. Japan HIV Prevention Drug Revenue (2020-2031) & (US$ Million)
Figure 57. South Korea HIV Prevention Drug Revenue (2020-2031) & (US$ Million)
Figure 58. China Taiwan HIV Prevention Drug Revenue (2020-2031) & (US$ Million)
Figure 59. India HIV Prevention Drug Revenue (2020-2031) & (US$ Million)
Figure 60. Central and South America HIV Prevention Drug Sales YoY (2020-2031) & (K Units)
Figure 61. Central and South America HIV Prevention Drug Revenue YoY (2020-2031) & (US$ Million)
Figure 62. Central and South America Top 5 Manufacturers HIV Prevention Drug Sales Revenue (US$ Million) in 2024
Figure 63. Central and South America HIV Prevention Drug Sales Volume (K Units) by Type (2021-2031)
Figure 64. Central and South America HIV Prevention Drug Sales Revenue (US$ Million) by Type (2020-2031)
Figure 65. Central and South America HIV Prevention Drug Sales Volume (K Units) by Application (2020-2031)
Figure 66. Central and South America HIV Prevention Drug Sales Revenue (US$ Million) by Application (2020-2031)
Figure 67. Brazil HIV Prevention Drug Revenue (2020-2025) & (US$ Million)
Figure 68. Argentina HIV Prevention Drug Revenue (2020-2025) & (US$ Million)
Figure 69. Middle East, and Africa HIV Prevention Drug Sales YoY (2020-2031) & (K Units)
Figure 70. Middle East and Africa HIV Prevention Drug Revenue YoY (2020-2031) & (US$ Million)
Figure 71. Middle East and Africa Top 5 Manufacturers HIV Prevention Drug Sales Revenue (US$ Million) in 2024
Figure 72. Middle East and Africa HIV Prevention Drug Sales Volume (K Units) by Type (2021-2031)
Figure 73. South America HIV Prevention Drug Sales Revenue (US$ Million) by Type (2020-2031)
Figure 74. Middle East and Africa HIV Prevention Drug Sales Volume (K Units) by Application (2020-2031)
Figure 75. Middle East and Africa HIV Prevention Drug Sales Revenue (US$ Million) by Application (2020-2031)
Figure 76. GCC Countries HIV Prevention Drug Revenue (2020-2025) & (US$ Million)
Figure 77. Turkey HIV Prevention Drug Revenue (2020-2025) & (US$ Million)
Figure 78. Egypt HIV Prevention Drug Revenue (2020-2025) & (US$ Million)
Figure 79. South Africa HIV Prevention Drug Revenue (2020-2025) & (US$ Million)
Figure 80. HIV Prevention Drug Industry Chain Mapping
Figure 81. Regional HIV Prevention Drug Manufacturing Base Distribution (%)
Figure 82. Global HIV Prevention Drug Production Market Share by Region (2020-2031)
Figure 83. HIV Prevention Drug Production Process
Figure 84. Regional HIV Prevention Drug Production Cost Structure
Figure 85. Channels of Distribution (Direct Vs Distribution)
Figure 86. Bottom-up and Top-down Approaches for This Report
Figure 87. Data Triangulation
Figure 88. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global UV Delayed Curing Adhesives Market Outlook, In‑Depth Analysis & Forecast to 2031
Nov 04, 25
Global Die-Casting Die Steel Market Outlook, In‑Depth Analysis & Forecast to 2031
Nov 04, 25
Global Adaptive Neuromodulation Therapy Devices Market Outlook, In‑Depth Analysis & Forecast to 2031
Nov 04, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232